This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: MediPharm Labs Corp.
Announces financial results for the three months ended March 31, 2025. During Q1 2025, the Company's revenue of $10.8M increased $1.0M or 11% versus the three months ended March 31, 2024, largely driven by the increased revenues generated by sales of flower and dronabinol in our international business The Company's Q1 2025 gross profit was $4.2M or 38.7% of total revenue and improved significantly versus the Q1 2024 gross profit margin of 27.4% due to increased sales volume, product mix and expense reductions. MediPharm Labs Corp. shares T.LABS are trading up $0.02 at $0.11.
